BVNKF:OTCMKTS
Bavarian Nordic A/S
US$33.66
arrow_upward
+0.01%(+0.0050) 1D
10월 7일, 오후 4시 0분 0초 GMT-4 · USD
search
모든 종목 코드
| 종목 코드 | 가격 | 변동 | 변동률(%) |
|---|
insights_autoBVNKF의 주요 통계 생성 중...
시가
US$33.66
고가
US$33.66
저가
US$33.66
시가총액
27.43억
평균 거래량
3.00
거래량
100.00
52주 최고가
US$37.22
52주 최저가
US$27.69
베타
1.46
유통 주식수
7926.50만
직원 수
2천
시가
US$33.66
고가
US$33.66
저가
US$33.66
시가총액
27.43억
평균 거래량
3.00
거래량
100.00
52주 최고가
US$37.22
52주 최저가
US$27.69
베타
1.46
유통 주식수
7926.50만
직원 수
2천
뉴스 기사
웹 소스 및 뉴스 파트너 제공
The Copenhagen Post
·
2시간 전
Bavarian Nordic raises 2026 revenue forecast on stronger travel vaccine sales
Investing.com
·
7시간 전
Why is Bavarian Nordic stock surging today?
Yahoo Finance
·
8시간 전
Bavarian Nordic lifts revenue, margin outlook on U.S. rabies vaccine demand
프로필
Bavarian Nordic A/S is a Danish biotechnology company focused on the development, manufacturing and commercialization of vaccines. The company is headquartered in Hellerup, Denmark, with manufacturing facilities in Kvistgård, Denmark and Thörishaus near Bern, Switzerland. The company has research and development facilities in Martinsried, Germany, as well as offices in USA, Canada, and France. The company uses viral vectors and virus-like particles in its research and development.
In July 2025, the company agreed to be acquired by private equity firms Permira and Nordic Capital for 19 billion kr. However, in November, the acquisition failed to gain sufficient support from Bavarian Nordic's shareholders, leading to its termination.
In 2026, Bavarian Nordic was ranked second in Time Magazine's World Most Impactful Companies. Wikipedia
Bavarian Nordic A/S에 관한 정보